TITLE

FDA launches plan to prevent unnecessary harm from medication use

AUTHOR(S)
Traynor, Kate
PUB. DATE
January 2010
SOURCE
American Journal of Health-System Pharmacy;1/1/2010, Vol. 67 Issue 1, p7
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the introduction of the U.S. Food and Drug Administration's (FDA's) Safe Use Initiative to prevent irrelevant harm from medication use. It notes that FDA is planning to work with the Centers for Disease Control and Prevention for the development of preventable medication harm based on population. It points out that FDA exceeds its mission of ensuring safe and effective medications. It also requires manufacturers to develop a risk evaluation and moderation strategy.
ACCESSION #
47426897

 

Related Articles

  • Nine Ideas to Make Tylenol and Other Acetaminophen Drugs Safer. Engelberg, Stephen; Fields, Robin // Pro Publica;9/25/2013, p1 

    The article reports on drug safety issues involving popular drugs in the U.S. including acetaminophen, the active ingredient of Tylenol, and the issues of deaths and injuries resulting from drug misuse. The author discusses the proposals by institutions like the U.S. Centers for Disease Control...

  • HEALTH AGENCIES UPDATE. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;11/26/2008, Vol. 300 Issue 20, p2259 

    The article presents news from several U.S. health agencies. Data from the U.S. Centers for Disease Control and Prevention shows that the U.S. continues to lag behind other industrialized countries in reducing infant mortality rates. The U.S. National Institute on Deafness and Other...

  • New Medication for Severe Malaria Available under an Investigational New Drug Protocol.  // Clinical Infectious Diseases;10/1/2007, Vol. 45 Issue 7, piii 

    The article reports that the U.S. Centers for Disease Control and Prevention's (CDC's) Investigational New Drug Application (IND) for intravenous artesunate went into effect on June 21, 2007. Under a protocol entitled "Intravenous Artesunate for Treatment of Severe Malaria in the United States,"...

  • Creating consistency in drug-safety programs. Menighan, Thomas E. // Pharmacy Today;Jun2010, Vol. 16 Issue 6, p8 

    The author reflects on the need for consistency in the implementation of drug-safety programs in the U.S. He states that the safe use of the complex drugs processed by the U.S. Food and Drug Administration (FDA) for approval must be ensured by requiring risk evaluation and mitigation strategies...

  • Adverse Events Associated with Administration of Simulation Intravenous Fluids to Patients -- United States, 2014. Robyn, Misha P.; Hunter, Jennifer C.; Burns, Amy; Newman, Alexandra P.; White, Jennifer; Clement, Ernest J.; Lutterloh, Emily; Quinn, Monica; Edens, Chris; Epstein, Lauren; Seiber, Kathy; Duc Nguyen; Kallen, Alexander; Blog, Debra // MMWR: Morbidity & Mortality Weekly Report;3/6/2015, Vol. 64 Issue 8, p226 

    The article reports on adverse events associated with the administration of simulation intravenous fluids to U.S. patients in 2014. Topics discussed include an investigation by the New York State Department of Health (NYSDOH) and the U.S. Centers for Disease Control and Prevention (CDC) into the...

  • Manufacturers argue against mandatory training for opioid prescribers. Traynor, Kate // American Journal of Health-System Pharmacy;1/15/2010, Vol. 67 Issue 2, p96 

    The article reports that manufacturers of opioid medications have requested U.S. Food and Drug Administration (FDA) to adopt a careful method for changing prescription practices as the agency develops a risk evaluation and mitigation strategy (REMS) for some of these medications. According to...

  • Cessation shelf is smokin'.  // Drug Store News;1/10/2011, Vol. 33 Issue 1, p46 

    The article reports on the programs initiated by the U.S. Centers for Disease Control and Prevention and the Food and Drug Administration.

  • Handwashing Versus Alcohol-Based Gels---FDA Information.  // Journal of Environmental Health;Sep2003, Vol. 66 Issue 2, p40 

    The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are working together to control the transmission of pathogens that can result in foodborne illnesses. Transmission of pathogenic bacteria, viruses, and parasites from raw food or from ill workers...

  • FDA, CDC award jobs worth up to $540m. Dickson, Virgil // PRWeek (U.S. Edition);Nov2012, Vol. 15 Issue 11, p7 

    The article discusses the Food and Drug Administration of the U.S. and the U.S. Centers for Disease Control and Prevention that has received 540 million dollars as a multi-year anti-smoking marketing contract.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics